Invention Grant
- Patent Title: Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
-
Application No.: US16025769Application Date: 2018-07-02
-
Publication No.: US11236393B2Publication Date: 2022-02-01
- Inventor: Jerome I. Rotter , Marla Dubinsky , Stephan R. Targan , Kent D. Taylor
- Applicant: CEDARS-SINAI MEDICAL CENTER
- Applicant Address: US CA Los Angeles
- Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee Address: US CA Los Angeles
- Agency: Wilson Sonsini Goodrich & Rosati
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12P19/34 ; C12Q1/6883
Abstract:
The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.
Public/Granted literature
- US20190010549A1 METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE Public/Granted day:2019-01-10
Information query
